Effects of tyramine administration in Parkinson's disease patients treated with selective MAO‐B inhibitor rasagiline
Citations Over TimeTop 10% of 2006 papers
Abstract
Rasagiline is a novel, potent, and selective MAO-B inhibitor shown to be effective for Parkinson's disease. Traditional nonselective MAO inhibitors have been associated with dietary tyramine interactions that can induce hypertensive reactions. To test safety, tyramine challenges (50-75 mg) were performed in 72 rasagiline-treated and 38 placebo-treated Parkinson's disease (PD) patients at the end of two double-blind placebo-controlled trials of rasagiline. An abnormal pressor response was prespecified as three consecutive measurements of systolic blood pressure (BP) increases of >or= 30 mm Hg and/or bradycardia of or= 30 mm Hg on three measurements. No subject on 1 mg/day rasagiline (0/12) experienced significant BP or heart rate changes following tyramine ingestion. These data demonstrate that rasagiline 0.5 to 2 mg daily is not associated with clinically significant tyramine reactions and can be used as monotherapy or adjunct to levodopa in PD patients without specific dietary tyramine restriction.
Related Papers
- → Comparison of Selegiline and Rasagiline Therapies in Parkinson Disease: A Real-life Study(2016)28 cited
- Comparative efficacy of selegiline versus rasagiline in the treatment of early Parkinson's disease.(2014)
- → Prescribing pattern and resource utilization of monoamine oxidase-B inhibitors in Parkinson treatment: comparison between rasagiline and selegiline(2015)11 cited
- → Effects of selegiline and rasagiline on disease progression in Parkinson’s disease(2012)4 cited
- → Effects of monoamine oxidase Type B inhibitors on motor and non-motor symptoms in Parkinson’s disease: A systematic comparison of rasagiline and selegiline(2012)3 cited